SummaryRMgm-332
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Introduction of a transgene |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 18799734 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | Not applicable |
Other information parent line | |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | R.J. Lundie; W.R. Heath |
Name Group/Department | Not applicable |
Name Institute | Walter and Eliza Hall Institute of Medical Research |
City | Parkville, Victoria 3050 |
Country | Australia |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-332 |
Principal name | PbTG |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | No |
top of page | |
Phenotype | |
Asexual blood stage | It was demonstrated that the 'polytope transgene' was functionally expressed, correctly processed, and presented by the host immune system for specific stimulation of CD4+ and CD8+ T cells during blood-stage infection (see 'Additional remarks phenotype'). |
Gametocyte/Gamete | Not tested |
Fertilization and ookinete | Not tested |
Oocyst | Not tested |
Sporozoite | Not tested |
Liver stage | Not tested |
Additional remarks phenotype | Mutant/mutation Evidence is presented indicating that bone marrow-derived DC were critical for the induction of T cell responses during blood-stage infection and data is presented that suggests that CD8α DC are the major antigen-presenting cells for CD8+ T cells during blood-stage infection, whereas CD4 DC play a more extensive role in CD4+ T cell stimulation. Other mutants
|
top of page | |||||||||||||||||||
Type and details of transgene | |||||||||||||||||||
Is the transgene Plasmodium derived | Transgene: not Plasmodium | ||||||||||||||||||
Transgene name | CD4+ and CD8+ T cell epitopes and B cell epitopes (OVA, HA, gB) fused to GFP | ||||||||||||||||||
top of page | |||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||
Inducable system used | No | ||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||
Type of plasmid/construct | Circular plasmid | ||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||
Selectable marker used to select the mutant parasite | tgdhfr | ||||||||||||||||||
Promoter of the selectable marker | pbdhfr | ||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||
Additional remarks genetic modification | Sequences of overlapping oligonucleotides designed for PCR amplification of the selected CD4+ and CD8+ T cell epitopes (OVA257–264 [SIINFEKL], H-2Kb restricted; OVA323–339 [KISQAVHAAHAEINEAG], I-Ab and IAd restricted; gB498–505 [SSIEFARL], H-2Kb restricted; HA518–526 [IYSTVASSL], H-2Kd restricted; and HA126–138 [HNTNGVTAACSHE], I-Ad restricted), B cell epitopes FLAG (DYKDDDK) and c-myc (EQKLISEEDL), and restriction sites to facilitate cloning are illustrated in Fig. S1. To construct the polytope, oligonucleotides (F1–F6 and R1–R6) were denatured at 94°C for 2 min and then annealed at 37°C for 10 min before the addition of Klenow enzyme for 30 min at 30°C. After a 10-min incubation at 75°C, a PCR was performed on the annealed oligonucleotides using PLATINUM TaqDNA polymerase High Fidelity Enzyme and oligonucleotides F1 (5′-AGGATCCATGGATTACAAGGATGACGAACGATAAGTTAG-3′) and R1 (5′-TGGATCCTCAAGATCTTCTAGACAGATCCTCTTCAGAGATTAG-3′). PCR conditions were 94°C denaturation, 50°C annealing, and 68°C for nucleotide extension, incubating for 30 sec at each step for a total of 30 cycles. BamHI restriction sites (bold) were introduced in F1 and R1 to facilitate cloning into the expression vector PbGFPCON. Unique BglII (italicized) and XbaI (italicized in bold) sites were introduced in R1 to enable fusion to GFP and orientation screening, respectively. To fuse the polytope to GFP, the polytope PCR product was first subcloned into the multicloning site of vector pGEM-Teasy (Promega). Digestion of this vector with BglII then created a compatible restriction site for the in-frame fusion of GFP (see Figure), released as a BamHI fragment from vector PbGFPCON. The final polytope-GFP fusion product was introduced as a BamHI fragment into the expression cassette of the expression plasmid PbGFPcon (see RMgm-5), to create vector PbTGFPcon. | ||||||||||||||||||
Additional remarks selection procedure | Transgenes were maintained as episomal plasmids under pyrimethamine selection in vivo. | ||||||||||||||||||
top of page | |||||||||||||||||||
Other details transgene | |||||||||||||||||||
top of page | |||||||||||||||||||
Promoter | |||||||||||||||||||
Gene Model of Parasite | PBANKA_1133300 | ||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1357100 | ||||||||||||||||||
Gene product | elongation factor 1-alpha | ||||||||||||||||||
Gene product: Alternative name | eef1a | ||||||||||||||||||
| |||||||||||||||||||
top of page | |||||||||||||||||||
3'-UTR | |||||||||||||||||||
Gene Model of Parasite | PBANKA_0719300 | ||||||||||||||||||
Gene product | bifunctional dihydrofolate reductase-thymidylate synthase, putative | ||||||||||||||||||
Gene product: Alternative name | dhfr/ts | ||||||||||||||||||
| |||||||||||||||||||
Insertion/Replacement locus | |||||||||||||||||||
Replacement / Insertion | Not available | ||||||||||||||||||
Gene Model of Parasite | Not available | ||||||||||||||||||
Gene product | Not available | ||||||||||||||||||
Gene product: Alternative name | |||||||||||||||||||
| |||||||||||||||||||
top of page |